Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Türkiye.
Faculty of Engineering and Life Sciences, Kütahya Health Sciences University, Kütahya, Türkiye.
Methods Mol Biol. 2024;2736:151-161. doi: 10.1007/7651_2023_497.
Leukemia stem cells (LSC) are thought to be the basis of leukemia progression since they are highly resistant to conventional chemotherapy. LSC isolation is critical in experimental studies, drug development, and application. Due to their likely hematopoietic stem cell (HSC) origin, LSCs have surface antigens that are similar to HSC. Surface markers such as CD34, CD123, CD133, and CD33 have been used extensively to assess LSCs. LSCs could be separated from other cells using magnetic selection (MS) or flow cytometry selection (FCS) methods using these markers. Understanding the role of LSCs in cancer progression and how to therapeutically target them in vitro and in vivo is critical for the development of LSC-targeting drug candidates. In this chapter, we set out to describe the primary human LSC purification and characterization processes used on patient samples with leukemia and lymphoma.
白血病干细胞（LSC）被认为是白血病进展的基础，因为它们对常规化疗具有高度抗性。LSC 的分离在实验研究、药物开发和应用中至关重要。由于它们可能起源于造血干细胞（HSC），LSCs 具有与 HSC 相似的表面抗原。表面标记物，如 CD34、CD123、CD133 和 CD33，已被广泛用于评估 LSCs。可以使用这些标记物通过磁选（MS）或流式细胞术选择（FCS）方法将 LSCs 从其他细胞中分离出来。了解 LSCs 在癌症进展中的作用以及如何在体外和体内对其进行治疗性靶向，对于开发针对 LSC 的药物候选物至关重要。在本章中，我们旨在描述用于白血病和淋巴瘤患者样本的主要人 LSC 纯化和表征过程。
